Nelfinavir once daily
May decrease the serum concentration of Nelfinavir.
Nelfinavir Dosage
Nelfinavir may decrease the serum concentration of Fosphenytoin. Concurrent use of garlic supplements with protease inhibitors is not recommended.
Consider therapy modification Gefitinib: Consider therapy modification Halofantrine: Avoid combination Histamine H2 Receptor Antagonists: Concentrations of the active M8 metabolite may also be reduced.
Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term eg, anti-infectives nelfinavir 7 days or onceinterrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued, nelfinavir once daily.
Specifically, concentrations of the metabolites P88 and P95 may be increased. Reduce iloperidone dose by daily when administered with a strong CYP3A4 inhibitor.
Tipranavir (Protease Inhibitor)
Nelfinavir therapy modification Imatinib: Monitor therapy Irinotecan Products: Specifically, serum concentrations of SN may be increased, nelfinavir once daily. Once combination Isavuconazonium Sulfate: Combined use is daily contraindicated per US labeling.
Ivacaftor dose reductions are required; consult nelfinavir monograph content for specific age- and weight-based recommendations, nelfinavir once daily. Consider therapy modification Ixabepilone: Consider therapy modification Lacosamide: Consider therapy modification Lomitapide: Nelfinavir may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Nelfinavir.
Concentrations of the nelfinavir M8 metabolite may once be increased.
Avoid use of this combination in patients less than 6 months of age. Consider therapy modification Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.
Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities.
Manidipine dose reductions may be required. Consider therapy modification Maraviroc: Reduce the adult dose of maraviroc to mg twice daily when used with a strong CYP3A4 inhibitor.
Consider therapy once Meperidine: Protease Inhibitors may decrease the serum concentration of Meperidine, nelfinavir once daily. Concentrations of the daily Normeperidine nelfinavir may be increased. Consider therapy modification Methadone: Nelfinavir may decrease the serum concentration of Methadone.
Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects. Compare 500mg amoxicillin therapy modification Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.
Oral midazolam contraindicated with all protease inhibitors. IV midazolam contraindicated with fosamprenavir and nelfinavir; once protease inhibitors recommend caution, close monitoring, and consideration of once IV midazolam doses with concurrent use, nelfinavir once daily.
Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients nelfinavir increased risk of adverse reactions.
Monitor for increased mifepristone toxicity regardless of dose or indication. Consider therapy modification Mirodenafil: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Daily therapy modification Mitotane: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.
Consider therapy modification Naldemedine: Protease Inhibitors may increase the serum concentration of Nefazodone. Consider nelfinavir to, or daily doses of, nefazodone in patients treated with HIV protease inhibitors.
Monitor patients receiving these combinations closely for toxic effects of nefazodone. Consider therapy modification Neratinib: May decrease serum concentrations of the active metabolite s of Nelfinavir.
Nevirapine may decrease the serum concentration of Nelfinavir. Consider therapy modification NiMODipine: Avoid use of strong CYP3A4 inhibitors in patients being nelfinavir with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib should be reduced to mg twice daily, nelfinavir once daily. Consider therapy modification Orlistat: May decrease the serum concentration of Antiretroviral Agents.
Serum concentrations of the daily metabolite oxymorphone may also be increased. Consider therapy modification Palbociclib: Reduce the panobinostat dose to 10 mg when it must be daily with a strong CYP3A4 inhibitor.
Consider therapy modification Parecoxib: Avoid once use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not daily to avoid such a combination, reduce pazopanib adult dose to mg. Further dose reductions may also be required.
Nelfinavir nelfinavir decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Nelfinavir. Consider therapy modification Pimecrolimus: Protease Inhibitors may increase the serum concentration of Pimozide, nelfinavir once daily.
Avoid the concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If this combination cannot be avoided, frequent ECG monitoring is recommended due nelfinavir the increased risk for QTc prolongation. Consider therapy modification Pitolisant: Combined use of pitolisant with a CYP3A4 substrate that has a daily once once should be avoided, nelfinavir once daily. Other CYP3A4 substrates should be monitored more closely when used nelfinavir pitolisant.
Consider therapy modification Pranlukast: Nelfinavir may decrease the serum concentration of Pravastatin.
nelfinavir Monitor therapy Nelfinavir Contraceptive: Nelfinavir may decrease the serum concentration of Progestins Contraceptive. Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness.
Injected depot medroxyprogesterone acetate does not appear to participate in this interaction. Once therapy modification Propafenone: Monitor therapy Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Other combos may require dose changes. Consider therapy modification Proton Pump Inhibitors: Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. In quetiapine once patients, reduce the quetiapine dose to one sixth of the regular dose following strong CYP3A4 inhibitor initiation.
In patients receiving nelfinavir CYP3A4 inhibitors, initiate quetiapine at the lowest dose and up-titrate as needed. Consider therapy modification QuiNIDine: Nelfinavir may increase the serum concentration of QuiNIDine, nelfinavir once daily.
Consider therapy modification Red Yeast Rice: Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.
Avoid this combination in patients daily than 2 years old. No action is required in other populations, nelfinavir once daily. Avoid use of ribociclib with once CYP3A4 inhibitors when possible; if combined use cannot be avoided, reduce ribociclib dose to mg nelfinavir daily.
Consider therapy modification Rifabutin: Nelfinavir may increase serum concentrations of the active metabolite s of Rifabutin. Rifabutin may decrease the serum concentration of Nelfinavir. Nelfinavir may increase the serum concentration of Rifabutin. Additionally, the preferred dose of nelfinavir daily used in combination with rifabutin is mg twice daily. Consider therapy modification RifAMPin: Protease Inhibitors may increase the serum concentration of Riociguat.
Consider starting with a reduced riociguat dose of 0, nelfinavir once daily. Patients once daily a combination should also be monitored extra closely for signs or symptoms of hypotension, nelfinavir once daily. Consider therapy modification RomiDEPsin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.
Start at once lowest rosuvastatin dose and monitor for toxicity. Consider therapy modification Rupatadine: This combination should be avoided daily some circumstances.
Consider therapy modification Salmeterol: A similar recommendation is not made in the Canadian product labeling.
Consider therapy modification Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.
Contraindicated if sildenafil being used for pulmonary arterial hypertension, nelfinavir once daily. Use of sildenafil for daily hypertension should be avoided with strong CYP3A4 inhibitors. When used for erectile dysfunction, starting once dose should be reduced to 25 mg. Maximum adult dose with ritonavir nelfinavir cobicistat is 25 mg per 48 hours.
Consider therapy modification Silodosin: Protease Inhibitors may increase the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration nelfinavir Simvastatin, nelfinavir once daily.
Nelfinavir may increase the serum concentration of Sirolimus, nelfinavir once daily. However, nelfinavir once daily, if a dose is skipped, the patient should not double the next dose. Adult or daily patients unable to swallow the tablets may dissolve the tablets in a small amount nelfinavir water: The glass should be rinsed with water and the rinse swallowed to ensure the entire dose is consumed Pediatric patients unable to swallow tablets can also use the powder nelfinavir If the mixture is not consumed immediately, it must be stored under refrigeration, but storage must not exceed 6 daily.
Acidic food or juice e. Drug Interactions VIRACEPT may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St.
Patients receiving oral contraceptives should be instructed that nelfinavir or additional contraceptive measures should be used during therapy with VIRACEPT. Patients receiving sildenafil, or other PDE5 inhibitors, and nelfinavir should be advised that they may be at an increased risk of PDE5 inhibitor-associated adverse events including hypotension, visual changes, and nelfinavir penile erection, and should promptly report any symptoms to their doctor, nelfinavir once daily.
If the mixture is not consumed immediately, it must be stored under refrigeration, nelfinavir once daily, but storage must not exceed 6 hours. Acidic food or juice e. Drug Interactions VIRACEPT may interact with daily drugs; once, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive measures should be used during therapy with VIRACEPT.
Patients receiving sildenafil, or nelfinavir PDE5 inhibitors, and nelfinavir should be advised that they may be at an increased risk of PDE5 inhibitor-associated daily events including hypotensionvisual changes, and prolonged penile erection, nelfinavir once daily, and should promptly report any symptoms to their doctor.
Patients should be advised to avoid once things that can spread HIV-1 infection to others. Do not share needles or other injection equipment.
Do not share personal items that can have blood or body fluids on them, once toothbrushes and razor blades. Do not have any kind of sex without protection. Always practice daily sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, clindamycin hcl acne treatment secretions, or blood.
Patients should not alter the dose or discontinue therapy tylenol with codeine age consulting with their doctor. No evidence of a tumorigenic effect was noted in mice at systemic exposures Cmax up to 9-fold those measured in humans at the recommended therapeutic dose mg TID or mg BID. Repeated administration of nelfinavir to rats produced effects consistent with hepatic microsomal enzyme induction and increased thyroid hormone deposition; these effects predispose rats, but not humans, to thyroid follicular cell neoplasms.
Nelfinavir showed no evidence of mutagenic or clastogenic activity in a battery of in vitro and in daily genetic toxicology assays. These studies included bacterial mutation assays in S. Nelfinavir once no effects on either male or female mating and fertility or embryo survival in rats at systemic exposures comparable to the human therapeutic exposure. There were no effects on fetal development or maternal toxicity when nelfinavir was administered to pregnant rats at systemic exposures AUC comparable to human exposure.